Prague, Czech Republic
Address:
|
Member Consultation & ALV documents available now |
Member Consultation for the Development of Vision 2.0:
ROADMAP FOR THE IMMUNOLOGICAL RESEARCH FIELD IN THE NETHERLANDS
Thursday December 12th, 11:30-12:30 hrs. in Room Boston 9
The NVVI board has established a committee to develop Vision 2.0 for animal-free innovation in the immunological research field. The importance of the immune system in health and disease is underscored by the fact that approximately 1 in 3 (to 4) candidate drugs currently in trials target the immune system. This involves both enhancing the immune response (e.g., vaccination and cancer) and suppressing immunity (e.g., allergy and autoimmune diseases). Consequently, 25 to 33% of new drugs fundamentally rely on excellent immunological research.
The committee has mapped out the opportunities and barriers for current and future high-quality immunological research with a minimal number of laboratory animals. A session has been included in the program of the congress in Noordwijkerhout to discuss this document with NVVI members. The session will be conducted in Dutch.
The documents for the upcoming Annual General Assembly (ALV) are now available.
Logged-in members can access the agenda, minutes, and annual reports under the "ALV" section located in the “About Us” menu on the website.
Stay informed about NVVI’s updates and plans.